Avenue Therapeutics Inc (ATXI) Stock: What Does the Chart Say Monday?

The market has been high on Avenue Therapeutics Inc (ATXI) stock recently. ATXI gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Avenue Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATXI!

See Full ATXI Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ATXI Stock Today?

Avenue Therapeutics Inc (ATXI) stock has fallen -6.24% while the S&P 500 has risen 0.49% as of 9:50 AM on Monday, Dec 27. ATXI is lower by -$0.06 from the previous closing price of $1.02 on volume of 33,134 shares. Over the past year the S&P 500 has gained 27.13% while ATXI is lower by -84.66%. ATXI lost -$0.23 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Avenue Therapeutics Inc click here.

More About Avenue Therapeutics Inc

Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain. Click Here to get the full Stock Report for Avenue Therapeutics Inc stock.